Saturday, May 18, 2024
HomeLatest Pharma-NewsUnited States Food and Drug Administration (USFDA) approved Bortezomib for Injection (IV)...

United States Food and Drug Administration (USFDA) approved Bortezomib for Injection (IV) 3.5 mg/vial for the treatment of cancers in adult patients

December 04, 2019: Dr Reddy’s Laboratories  launched Bortezomib for Injection (IV) 3.5 mg/vial for the treatment of certain types of cancers in adult patients, in the US market approved by the United States Food and Drug Administration (USFDA).

This product is for intravenous use only for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who already  received at least one prior therapy.

Each vial contains 3.5 mg bortezomib (as a mannitol boronic ester) that After reconstitution, 1 ml of solution for intravenous injection contains 1 mg  bortezomib. https://www.drugs.com/uk/bortezomib-dr-reddys-3-5-mg-powder-for-solution-for-injection-leaflet.html

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular